» Articles » PMID: 6191050

Pre-treatment and Post-treatment Evaluation of Prostatic Adenocarcinoma for Prostatic Specific Acid Phosphatase and Prostatic Specific Antigen by Immunohistochemistry

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 1983 Jul 1
PMID 6191050
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Prostatic specific acid phosphatase and prostatic specific antigen have been used as specific markers of prostatic adenocarcinoma in immunohistochemical studies, particularly when seeking the primary site of a poorly differentiated metastasis. We herein evaluate the effect of therapy on the persistence of these markers in surgically obtained tissues. Prostatic biopsies from 30 patients with adenocarcinoma of the prostate gland before and after treatment with orchiectomy alone, diethylstilbestrol, external beam radiation or combined radiation and diethylstilbestrol were studied for prostatic specific acid phosphatase and prostatic specific antigen using the indirect immunoperoxidase technique. The interval between biopsies ranged from 3 to 72 months, with an average of 28 months. All pre-treatment biopsies stained positively for prostatic specific acid phosphatase and prostatic specific antigen. Staining for prostatic specific antigen and prostatic specific acid phosphatase was seen easily in 29 of 30 post-treatment biopsies, while in 1 case infiltrating anaplastic cells surrounded by stroma showed staining for these antigens in an extremely small percentage of cells, which were overlooked easily unless examined carefully. In view of this small number of positively staining cells this case was designated as equivocal. While some cases demonstrated less intense staining in post-treatment biopsies compared to pre-treatment, this finding was by no means constant. With these primary antisera a higher percentage of cytologically malignant cells stained positively for prostatic specific acid phosphatase than for prostatic specific antigen in adjacent tissue sections in some cases. Prostatic specific acid phosphatase and prostatic specific antigen appear to be sensitive and persistent markers of prostatic adenocarcinoma despite morphologic changes accompanying various therapies.

Citing Articles

The Effects of Extract on Testosterone-Induced Benign Prostatic Hyperplasia in Rats, and Quantitative Analysis of Major Constituents Depending on Extract Conditions.

Kim N, Jegal J, Kim Y, Heo J, Rho J, Yang M Nutrients. 2020; 12(6).

PMID: 32481550 PMC: 7352698. DOI: 10.3390/nu12061575.


Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells.

Zhang Y, Ni J, Messing E, Chang E, Yang C, Yeh S Proc Natl Acad Sci U S A. 2002; 99(11):7408-13.

PMID: 12032296 PMC: 124244. DOI: 10.1073/pnas.102014399.


Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens.

Berner A, Nesland J, Waehre H, Silde J, Fossa S Br J Cancer. 1993; 68(2):380-4.

PMID: 7688548 PMC: 1968568. DOI: 10.1038/bjc.1993.344.


Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.

Ruizeveld de Winter J, Janssen P, Sleddens H, Trapman J, Brinkmann A, Santerse A Am J Pathol. 1994; 144(4):735-46.

PMID: 7512791 PMC: 1887232.


Epithelial markers in prostatic, bladder, and colorectal cancer: an immunoperoxidase study of epithelial membrane antigen, carcinoembryonic antigen, and prostatic acid phosphatase.

Heyderman E, Brown B, Richardson T J Clin Pathol. 1984; 37(12):1363-9.

PMID: 6392348 PMC: 499028. DOI: 10.1136/jcp.37.12.1363.